These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21525570)

  • 1. Drug discovery for neurodegenerative diseases: challenges and novel biochemical targets dedicated to the memory of Mark A. Smith for his inspiring contribution to Alzheimer's disease.
    Britton GB; Smith MA; Perry G; Sambamurti K; Jagannatha Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():1-2. PubMed ID: 21525570
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic opportunities for caffeine in Alzheimer's disease and other neurodegenerative disorders.
    de Mendonça A; Cunha RA
    J Alzheimers Dis; 2010; 20 Suppl 1():S1-2. PubMed ID: 20448305
    [No Abstract]   [Full Text] [Related]  

  • 3. A century-old debate on protein aggregation and neurodegeneration enters the clinic.
    Lansbury PT; Lashuel HA
    Nature; 2006 Oct; 443(7113):774-9. PubMed ID: 17051203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neurodegenerative disorders: the role of genetic factors in their origin and the efficiency of treatment].
    Sukhanov VA; Ionov ID; Piruzian LA
    Fiziol Cheloveka; 2005; 31(4):119-30. PubMed ID: 16122046
    [No Abstract]   [Full Text] [Related]  

  • 5. Foreword: neurodegenerative diseases: challenges and opportunities.
    Cuny GD
    Future Med Chem; 2012 Sep; 4(13):1647-9. PubMed ID: 22924500
    [No Abstract]   [Full Text] [Related]  

  • 6. Oltipraz may be useful in the prevention or treatment of Alzheimer's disease.
    Gharibzadeh S; Hoseini SS; Mahdavi S
    Med Hypotheses; 2007; 68(4):915-6. PubMed ID: 17222521
    [No Abstract]   [Full Text] [Related]  

  • 7. Neural stem cells, acetylcholine and Alzheimer's disease.
    Fullwood NJ
    Nat Chem Biol; 2007 Aug; 3(8):435. PubMed ID: 17637767
    [No Abstract]   [Full Text] [Related]  

  • 8. Proteopathy: the next therapeutic frontier?
    Walker LC; LeVine H
    Curr Opin Investig Drugs; 2002 May; 3(5):782-7. PubMed ID: 12090553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Discovery for Neurodegeneration - inaugural Alzheimer's Drug Discovery Foundation meeting.
    Fallon L
    IDrugs; 2007 Apr; 10(4):233-6. PubMed ID: 17390241
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network dysfunction perspective on neurodegenerative diseases.
    Palop JJ; Chin J; Mucke L
    Nature; 2006 Oct; 443(7113):768-73. PubMed ID: 17051202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An alternative approach to drug discovery for Alzheimer's disease dementia.
    Schubert D; Maher P
    Future Med Chem; 2012 Sep; 4(13):1681-8. PubMed ID: 22924506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects.
    Cedazo-Minguez A; Winblad B
    Exp Gerontol; 2010 Jan; 45(1):5-14. PubMed ID: 19796673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk in CNS drug discovery: focus on treatment of Alzheimer's disease.
    Pritchard JF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S1. PubMed ID: 19090998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of neurodegenerative diseases: emerging targets, treatments and technologies.
    Voss J; Ebert A; Wolfe M; Lindsley C; Cookson M; Deane R
    Future Med Chem; 2012 Sep; 4(13):1661-9. PubMed ID: 22924504
    [No Abstract]   [Full Text] [Related]  

  • 16. Modeling neurodegenerative diseases using stem cells: is it accelerating drug discovery?
    Ebert AD
    Future Med Chem; 2012 Sep; 4(13):1651-3. PubMed ID: 22924501
    [No Abstract]   [Full Text] [Related]  

  • 17. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM; van Dam AM; Drukarch B
    Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin E and other endogenous antioxidants in the central nervous system.
    Vatassery GT
    Geriatrics; 1998 Sep; 53 Suppl 1():S25-7. PubMed ID: 9745632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-target-directed ligands to combat neurodegenerative diseases.
    Cavalli A; Bolognesi ML; Minarini A; Rosini M; Tumiatti V; Recanatini M; Melchiorre C
    J Med Chem; 2008 Feb; 51(3):347-72. PubMed ID: 18181565
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.